Bookmark
Forward
QuickView for Cefepime (compound)
PubChem
| Name: | cefepime |
|---|---|
| PubChem Compound ID: | 2622 |
| Molecular formula: | C19H24N6O5S2 |
| Molecular weight: | 480.563 g/mol |
DrugBank
Identification
| Name: | cefepime |
|---|---|
| Name (isomeric): | DB01413 |
| Drug Type: | small molecule |
| Synonyms: |
Cefepimum [latin]; Cefepima [spanish]
|
| Brand: | Maxipime, Cepimax, Cepimex, Maxcef, Axepim |
| Category: | Cephalosporins, Anti-Bacterial Agents, Antibacterial Agents |
| CAS number: | 88040-23-7 |
Pharmacology
| Indication: | For the treatment of pneumonia (moderate to severe) caused by <i>Streptococcus pneumoniae</i>, including cases associated with concurrent bacteremia, <i>Pseudomonas aeruginosa</i>, <i>Klebsiella pneumoniae</i>, or <i>Enterobacter</i> species. Also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by <i>Escherichia coli</i> or <i>Klebsiella pneumoniae</i>, when the infection is severe, or caused by <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, or <i>Proteus mirabilis</i>, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Also for the treatment of uncomplicated skin and skin structure infections caused by <i>Staphylococcus aureus</i> (methicillin-susceptible strains only) or <i>Streptococcus pyogenes</i> and complicated intra-abdominal infections (used in combination with metronidazole) caused by <i>Escherichia coli</i>, viridans group streptococci, <i>Pseudomonas aeruginosa</i>, <i>Klebsiella pneumoniae</i>, <i>Enterobacter</i> species, or <i>Bacteroides fragilis</i>. |
|---|---|
| Pharmacology: |
Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. Cefepime has good activity against important pathogens including Pseudo...
show more » |
| Mechanism of Action: |
Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation s...
show more » |
| Absorption: | The absolute bioavailability of cefepime after an IM dose of 50 mg/kg was 82.3 (±15)% in eight patients. |
| Protein binding: | The serum protein binding of cefepime is approximately 20% and is independent of its concentration in serum. |
| Biotransformation: | Hepatic. Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide). |
| Route of elimination: | Elimination of cefepime is principally via renal excretion with an average (±SD) half-life of 2 (±0.3) hours and total body clearance of 120 (±8) mL/min in healthy volunteers. Cefepime is excreted in human milk. |
| Half Life: | 2.0 (± 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (± 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (± 2.0) hours. |
| Clearance: | 120 mL/min [Healthy adult male receiving a single 30-minute IV infusions of cefepime] 3.3 +/-1.0 mL/min/kg [Petriatic patients (2 months – 11 years of age) receiving a single IV dose] |
| Toxicity: | Symptoms of overdose include seizures, encephalopathy, and neuromuscular excitability. |
| Affected organisms: | Enteric bacteria and other eubacteria |
Interactions
| Drug interaction: |
|
|---|
Targets
Transporters
